Epigallocatechin-3-gallate induces autophagy-related apoptosis associated with LC3B II and Beclin expression of bladder cancer cells
- PMID: 33997996
- DOI: 10.1111/jfbc.13758
Epigallocatechin-3-gallate induces autophagy-related apoptosis associated with LC3B II and Beclin expression of bladder cancer cells
Abstract
The incidence of bladder cancer in traditional green tea-consuming countries was dramatically lower than low green tea-consuming countries. Epigallocatechin-3-gallate (EGCG), an active ingredient extracted from green tea, showed effective inhibition of formation and progression of many tumors. However, whether autophagy involved in this tumor-suppression mechanism of EGCG on bladder cancer was still unclear. In this study, we demonstrated low concentration of EGCG-induced proliferation inhibition and increased apoptosis in bladder cancer cell lines (5,637 and T24 cells) indicated by the increased expression of apoptosis-related protein (caspase9, caspase3 and BAX). In addition, low dose of EGCG also regulated autophagy pathway associated protein (LC3B II and Beclin) expression and this autophagy pathway was blocked by PI3K/AKT inhibitor; moreover, knockdown of ATG5 reversed EGCG-induced apoptosis in 5,637 cells, indicating that EGCG might inhibit the bladder cancer through autophagy pathway. Our findings indicated that EGCG should be considered as a novel therapy for bladder cancer treatment by regulating autophagy pathway. PRACTICAL APPLICATIONS: Our research proved EGCG from green tea could be used as an effective anti-tumor ingredient by revealing another mechanism that epigallocatechin-3-Gallate inhibited bladder cancer cells via inducing autophagy-related apoptosis. And green tea could be considered as a kind of tumor-preventing beverage.
Keywords: apoptosis; autophagy; bladder cancer; epigallocatechin-3-gallate.
© 2021 Wiley Periodicals LLC.
Similar articles
-
Epigallocatechin gallate sensitizes cisplatin-resistant oral cancer CAR cell apoptosis and autophagy through stimulating AKT/STAT3 pathway and suppressing multidrug resistance 1 signaling.Environ Toxicol. 2017 Mar;32(3):845-855. doi: 10.1002/tox.22284. Epub 2016 May 20. Environ Toxicol. 2017. PMID: 27200496
-
MicroRNA-384-5p/Beclin-1 As Potential Indicators For Epigallocatechin Gallate Against Cardiomyocytes Ischemia Reperfusion Injury By Inhibiting Autophagy Via PI3K/Akt Pathway.Drug Des Devel Ther. 2019 Oct 17;13:3607-3623. doi: 10.2147/DDDT.S219074. eCollection 2019. Drug Des Devel Ther. 2019. PMID: 31802847 Free PMC article.
-
Suppressing glucose metabolism with epigallocatechin-3-gallate (EGCG) reduces breast cancer cell growth in preclinical models.Food Funct. 2018 Nov 14;9(11):5682-5696. doi: 10.1039/c8fo01397g. Food Funct. 2018. PMID: 30310905 Free PMC article.
-
The Potential of Epigallocatechin Gallate (EGCG) in _targeting Autophagy for Cancer Treatment: A Narrative Review.Int J Mol Sci. 2022 May 28;23(11):6075. doi: 10.3390/ijms23116075. Int J Mol Sci. 2022. PMID: 35682754 Free PMC article. Review.
-
Molecular _targets of Epigallocatechin-Gallate (EGCG): A Special Focus on Signal Transduction and Cancer.Nutrients. 2018 Dec 6;10(12):1936. doi: 10.3390/nu10121936. Nutrients. 2018. PMID: 30563268 Free PMC article. Review.
Cited by
-
Resveratrol, Epigallocatechin Gallate and Curcumin for Cancer Therapy: Challenges from Their Pro-Apoptotic Properties.Life (Basel). 2023 Jan 17;13(2):261. doi: 10.3390/life13020261. Life (Basel). 2023. PMID: 36836619 Free PMC article. Review.
-
LC-MS Based Metabolomics Study of the Effects of EGCG on A549 Cells.Front Pharmacol. 2021 Sep 28;12:732716. doi: 10.3389/fphar.2021.732716. eCollection 2021. Front Pharmacol. 2021. PMID: 34650434 Free PMC article.
-
Autophagy in Its (Proper) Context: Molecular Basis, Biological Relevance, Pharmacological Modulation, and Lifestyle Medicine.Int J Biol Sci. 2024 Apr 22;20(7):2532-2554. doi: 10.7150/ijbs.95122. eCollection 2024. Int J Biol Sci. 2024. PMID: 38725847 Free PMC article. Review.
-
Apoptosis related genes mediated molecular subtypes depict the hallmarks of the tumor microenvironment and guide immunotherapy in bladder cancer.BMC Med Genomics. 2023 Apr 28;16(1):88. doi: 10.1186/s12920-023-01525-8. BMC Med Genomics. 2023. PMID: 37118734 Free PMC article.
-
Properties of flavonoids in the treatment of bladder cancer (Review).Exp Ther Med. 2022 Sep 19;24(5):676. doi: 10.3892/etm.2022.11612. eCollection 2022 Nov. Exp Ther Med. 2022. PMID: 36185766 Free PMC article. Review.
References
REFERENCES
-
- Amaravadi, R. K., Yu, D., Lum, J. J., Bui, T., Christophorou, M. A., Evan, G. I., Thomas-Tikhonenko, A., & Thompson, C. B. (2007). Autophagy inhibition enhances therapy-induced apoptosis in a Myc-induced model of lymphoma. Journal of Clinical Investigation, 117, 326-336. https://doi.org/10.1172/JCI28833
-
- Bimonte, S., & Cascella, M. (2020). The potential roles of epigallocatechin-3-gallate in the treatment of ovarian cancer: current state of knowledge. Drug Design, Development and Therapy, 14, 4245-4250. https://doi.org/10.2147/DDDT.S253092
-
- Bray, F., Ferlay, J., Soerjomataram, I., Siegel, R. L., Torre, L. A., & Jemal, A. (2018). Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: A Cancer Journal for Clinicians, 68, 394-424. https://doi.org/10.3322/caac.21492
-
- Cai, N., Dai, S. D., Liu, N. N., Liu, L. M., Zhao, N., & Chen, L. (2012). PI3K/AKT/mTOR signaling pathway inhibitors in proliferation of retinal pigment epithelial cells. International Journal of Ophthalmology, 5, 675-680. https://doi.org/10.3980/j.issn.2222-3959.2012.06.05
-
- Chen, X., Tong, R., Liu, B., Liu, H., Feng, X., Ding, S., Lei, Q., Tang, G., Wu, J., & Fang, W. (2020). Duo of (-)-epigallocatechin-3-gallate and doxorubicin loaded by polydopamine coating ZIF-8 in the regulation of autophagy for chemo-photothermal synergistic therapy. Biomaterials Science, 8, 1380-1393. https://doi.org/10.1039/c9bm01614g
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials